Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

Benzinga Newsdesk www.benzinga.com Negative 90.0%

Neg 90% Neu 0% Pos 0%

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $12 to $9.